These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26481647)

  • 1. Societal Implications of Health Insurance Coverage for Medically Necessary Services in the U.S. Transgender Population: A Cost-Effectiveness Analysis.
    Padula WV; Heru S; Campbell JD
    J Gen Intern Med; 2016 Apr; 31(4):394-401. PubMed ID: 26481647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis.
    Sheng G; Chen S; Dong C; Zhang R; Miao M; Wu D; Tan SC; Liu C; Xiong T
    J Med Econ; 2017 Apr; 20(4):371-381. PubMed ID: 27936995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coverage for Gender-Affirming Care: Making Health Insurance Work for Transgender Americans.
    Padula WV; Baker K
    LGBT Health; 2017 Aug; 4(4):244-247. PubMed ID: 28708447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations Between Transgender Exclusion Prohibitions and Insurance Coverage of Gender-Affirming Surgery.
    Almazan AN; Benson TA; Boskey ER; Ganor O
    LGBT Health; 2020 Jul; 7(5):254-263. PubMed ID: 32380882
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of alternative treatments for depression in low-income women.
    Beil H; Beeber LS; Schwartz TA; Lewis G
    J Ment Health Policy Econ; 2013 Jun; 16(2):55-65. PubMed ID: 23999203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States.
    Vanness DJ; Lomas J; Ahn H
    Ann Intern Med; 2021 Jan; 174(1):25-32. PubMed ID: 33136426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insurance Coverage and Use of Hormones Among Transgender Respondents to a National Survey.
    Stroumsa D; Crissman HP; Dalton VK; Kolenic G; Richardson CR
    Ann Fam Med; 2020 Nov; 18(6):528-534. PubMed ID: 33168681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Legislations and policies to expand mental health and substance abuse benefits in health insurance plans: a community guide systematic economic review.
    Jacob V; Qu S; Chattopadhyay S; Sipe TA; Knopf JA; Goetzel RZ; Finnie R; Thota AB;
    J Ment Health Policy Econ; 2015 Mar; 18(1):39-48. PubMed ID: 25862203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Insurance Coverage of Permanent Hair Removal in Transgender and Gender-Minority Patients.
    Thoreson N; Marks DH; Peebles JK; King DS; Dommasch E
    JAMA Dermatol; 2020 May; 156(5):561-565. PubMed ID: 32211825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
    Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
    J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-Effectiveness of Ivermectin 1% Cream in Adults with Papulopustular Rosacea in the United States.
    Taieb A; Stein Gold L; Feldman SR; Dansk V; Bertranou E
    J Manag Care Spec Pharm; 2016 Jun; 22(6):654-65. PubMed ID: 27231793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer's Perspective?
    Albright RH; Joseph RM; Wukich DK; Armstrong DG; Fleischer AE
    Clin Orthop Relat Res; 2020 Dec; 478(12):2869-2888. PubMed ID: 32694315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
    JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transgender-Related Insurance Denials as Barriers to Transgender Healthcare: Differences in Experience by Insurance Type.
    Bakko M; Kattari SK
    J Gen Intern Med; 2020 Jun; 35(6):1693-1700. PubMed ID: 32128693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
    Neilan AM; Landovitz RJ; Le MH; Grinsztejn B; Freedberg KA; McCauley M; Wattananimitgul N; Cohen MS; Ciaranello AL; Clement ME; Reddy KP; Hyle EP; Paltiel AD; Walensky RP
    Ann Intern Med; 2022 Apr; 175(4):479-489. PubMed ID: 35099992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Utility Analysis of Extending Public Health Insurance Coverage to Include Diabetic Retinopathy Screening by Optometrists.
    van Katwyk S; Jin YP; Trope GE; Buys Y; Masucci L; Wedge R; Flanagan J; Brent MH; El-Defrawy S; Tu HA; Thavorn K
    Value Health; 2017 Sep; 20(8):1034-1040. PubMed ID: 28964434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
    Phisalprapa P; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.